Fragile X mental retardation protein replacement restores hippocampal synaptic function in a mouse model of fragile X syndrome (original) (raw)

• Pieretti M, Zhang FP, Fu YH, Warren ST, Oostra BA, Caskey CT et al. Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 1991; 66: 817–822.
  Article CAS Google Scholar
• Verheij C, Bakker CE, de Graaff E, Keulemans J, Willemsen R, Verkerk AJ et al. Characterization and localization of the FMR-1 gene product associated with fragile X syndrome. Nature 1993; 363: 722–724.
  Article CAS Google Scholar
• Verkerk AJ, Pieretti M, Sutcliffe JS, Fu YH, Kuhl DP, Pizzuti A et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 1991; 65: 905–914.
  Article CAS Google Scholar
• Oberle I, Rousseau F, Heitz D, Kretz C, Devys D, Hanauer A et al. Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome. Science 1991; 252: 1097–1102.
  Article CAS Google Scholar
• O’Donnell WT, Warren ST . A decade of molecular studies of fragile X syndrome. Annu Rev Neurosci 2002; 25: 315–338.
  Article Google Scholar
• Huber KM, Gallagher SM, Warren ST, Bear MF . Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci USA 2002; 99: 7746–7750.
  Article CAS Google Scholar
• Nosyreva ED, Huber KM . Metabotropic receptor-dependent long-term depression persists in the absence of protein synthesis in the mouse model of fragile X syndrome. J Neurophysiol 2006; 95: 3291–3295.
  Article CAS Google Scholar
• Bliss TV, Collingridge GL . A synaptic model of memory: long-term potentiation in the hippocampus. Nature 1993; 361: 31–39.
  Article CAS Google Scholar
• Mulkey RM, Malenka RC . Mechanisms underlying induction of homosynaptic long-term depression in area CA1 of the hippocampus. Neuron 1992; 9: 967–975.
  Article CAS Google Scholar
• Pfeiffer BE, Huber KM . Current advances in local protein synthesis and synaptic plasticity. J Neurosci 2006; 26: 7147–7150.
  Article CAS Google Scholar
• Sutton MA, Schuman EM . Local translational control in dendrites and its role in long-term synaptic plasticity. J Neurobiol 2005; 64: 116–131.
  Article CAS Google Scholar
• Ashley Jr CT, Wilkinson KD, Reines D, Warren ST . FMR1 protein: conserved RNP family domains and selective RNA binding. Science 1993; 262: 563–566.
  Article CAS Google Scholar
• Feng Y, Gutekunst CA, Eberhart DE, Yi H, Warren ST, Hersch SM et al. Fragile X mental retardation protein: nucleocytoplasmic shuttling and association with somatodendritic ribosomes. J Neurosci 1997; 17: 1539–1547.
  Article CAS Google Scholar
• Kooy RF, Willemsen R, Oostra BA . Fragile X syndrome at the turn of the century. Mol Med Today 2000; 6: 193–198.
  Article CAS Google Scholar
• The Dutch-Belgian Fragile X Consortium. Fmr1 knockout mice: a model to study fragile X mental retardation. The Dutch-Belgian Fragile X Consortium. Cell 1994; 78: 23–33.
  Google Scholar
• Weiler IJ, Irwin SA, Klintsova AY, Spencer CM, Brazelton AD, Miyashiro K et al. Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation. Proc Natl Acad Sci USA 1997; 94: 5395–5400.
  Article CAS Google Scholar
• Burger C, Nash K, Mandel RJ . Recombinant adeno-associated viral vectors in the nervous system. Hum Gene Ther 2005; 16: 781–791.
  Article CAS Google Scholar
• Peden CS, Burger C, Muzyczka N, Mandel RJ . Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain. J Virol 2004; 78: 6344–6359.
  Article CAS Google Scholar
• Mandel RJ, Manfredsson FP, Foust KD, Rising A, Reimsnider S, Nash K et al. Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders. Mol Ther 2006; 13: 463–483.
  Article CAS Google Scholar
• Xu L, Daly T, Gao C, Flotte TR, Song S, Byrne BJ et al. CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice. Hum Gene Ther 2001; 12: 563–573.
  Article CAS Google Scholar
• Doll RF, Crandall JE, Dyer CA, Aucoin JM, Smith F . Comparison of promoter strengths on gene delivery into mammalian brain cells using AAV vectors. Gene Therapy 1996; 3: 437–447.
  CAS PubMed Google Scholar
• Burger C, Gorbatyuk OS, Velardo MJ, Peden CS, Williams P, Zolotukhin S et al. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2 and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther 2004; 10: 302–317.
  Article CAS Google Scholar
• Bear MF, Huber KM, Warren ST . The mGluR theory of fragile X mental retardation. Trends Neurosci 2004; 27: 370–377.
  Article CAS Google Scholar
• Nosyreva ED, Huber KM . Developmental switch in synaptic mechanisms of hippocampal metabotropic glutamate receptor-dependent long-term depression. J Neurosci 2005; 25: 2992–3001.
  Article CAS Google Scholar
• Musumeci SA, Calabrese G, Bonaccorso CM, D’Antoni S, Brouwer JR, Bakker CE et al. Audiogenic seizure susceptibility is reduced in fragile X knockout mice after introduction of FMR1 transgenes. Exp Neurol 2007; 203: 233–240.
  Article CAS Google Scholar
• Brown V, Small K, Lakkis L, Feng Y, Gunter C, Wilkinson KD et al. Purified recombinant Fmrp exhibits selective RNA binding as an intrinsic property of the fragile X mental retardation protein. J Biol Chem 1998; 273: 15521–15527.
  Article CAS Google Scholar
• Lo WD, Qu G, Sferra TJ, Clark R, Chen R, Johnson PR et al. Adeno-associated virus-mediated gene transfer to the brain: duration and modulation of expression. Hum Gene Ther 1999; 10: 201–213.
  Article CAS Google Scholar
• Rattazzi MC, LaFauci G, Brown WT . Prospects for gene therapy in the fragile X syndrome. Ment Retard Dev Disabil Res Rev 2004; 10: 75–81.
  Article Google Scholar
• Gantois I, Bakker CE, Reyniers E, Willemsen R, D’Hooge R, De Deyn PP et al. Restoring the phenotype of fragile X syndrome: insight from the mouse model. Curr Mol Med 2001; 1: 447–455.
  Article CAS Google Scholar
• Huber KM, Roder JC, Bear MF . Chemical induction of mGluR5- and protein synthesis—dependent long-term depression in hippocampal area CA1. J Neurophysiol 2001; 86: 321–325.
  Article CAS Google Scholar
• Hou L, Antion MD, Hu D, Spencer CM, Paylor R, Klann E . Dynamic translational and proteasomal regulation of fragile X mental retardation protein controls mGluR-dependent long-term depression. Neuron 2006; 51: 441–454.
  Article CAS Google Scholar
• Peier AM, McIlwain KL, Kenneson A, Warren ST, Paylor R, Nelson DL . (Over)correction of FMR1 deficiency with YAC transgenics: behavioral and physical features. Hum Mol Genet 2000; 9: 1145–1159.
  Article CAS Google Scholar
• Denman RB, Sung YJ . Species-specific and isoform-specific RNA binding of human and mouse fragile X mental retardation proteins. Biochem Biophys Res Commun 2002; 292: 1063–1069.
  Article CAS Google Scholar
• Xu R, Janson CG, Mastakov M, Lawlor P, Young D, Mouravlev A . Quantitative comparison of expression with adeno-associated virus (AAV-2) brain-specific gene cassettes. Gene Therapy 2001; 8: 1323–1332.
  Article CAS Google Scholar
• Graham FL, Smiley J, Russell WC, Nairn R . Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977; 36: 59–74.
  Article CAS Google Scholar
• Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M, Chesnut K et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Therapy 1999; 6: 973–985.
  Article CAS Google Scholar
• Zolotukhin S, Potter M, Zolotukhin I, Sakai Y, Loiler S, Fraites Jr TJ et al. Production and purification of serotype 1, 2 and 5 recombinant adeno-associated viral vectors. Methods 2002; 28: 158–167.
  Article CAS Google Scholar